Latest Reports

The “2025 Glaucoma Pharmaceuticals Market Report” analyzes the global and regional markets for glaucoma pharmaceuticals, identifying important trends and key factors for future success. The report provides forecasts through 2030 for branded prostaglandins, generic prostaglandins, beta blockers, carbonic anhydrase inhibitors, alpha agonists, fixed combo drugs, NO-donating compounds, and Rho-kinase inhibitors. The report also extensively discusses pipeline products, covering over 30 drug candidates that are currently under development. Additionally, 25 glaucoma pharmaceutical companies are profiled, with discussion of their products, strategic market position, background, and outlook. 

The “2024 Ophthalmic Laser Market Report” offers a comprehensive analysis of the global market for ophthalmic lasers, as well as a discussion of important trends and key factors shaping future success. The report covers photocoagulation, photodisruption, and SLT lasers with market data for 2023 and forecasts through 2029. Product demand is forecast in units and dollars, and market share is analyzed by product category.  Seventeen market competitors are profiled, with discussion of their products, strategic market position, background, and outlook. 

This report is designed for ophthalmic industry manufacturers, market analysts, providers, and investors who are interested in the ophthalmic lasers business and related products. In-depth topics include laser treatment estimates, ophthalmic surgeons using lasers, and manufacturers of ophthalmic lasers (excluding femtosecond and excimer lasers). 

The “2025 Retinal Device Market Report” provides in-depth analysis of the global retinal device market, examining the market’s size and growth, as well as identifying important developments that may shape its future. The analysis focuses on the 2024 market and forecasts market growth and evolution through 2029. Additionally, 19 retina device companies are profiled, with discussion of their products, strategic market position, background, and outlook. 

Market Scope’s "2024 Corneal Disease Model" offers extensive country-level prevalence data and five-year forecasts for nine corneal diseases for all countries with a population over a million.

This proprietary model takes into consideration the latest clinical research and demographic projections on a global scale and can be customized by geography and disease category to meet clients’ diverse needs. Disease models can be used to evaluate target markets for clinical-stage and commercial-stage products and gain insights into the volume and demographics of diseased populations.

The “2024 Optical Coherence Tomography Market Report” provides a comprehensive analysis of the global market for OCT imagers and forecasts market performance over the next five years. It analyzes the market drivers for the OCT segment, including providers, related diseases, competitive forces, and market trends.

Market estimates are divided into six categories: basic OCT models, advanced OCT models, combination OCT/fundus systems, combination OCT/SLO systems, intraoperative OCT, and OCTA. Estimates are included for unit sales, installed equipment base, and average prices.

Additionally, 12 OCT manufacturers are profiled, with discussion of their products, strategic market position, background, and outlook.

Market Scope’s “2024 Dry Eye Products Market Report” analyzes the current marketplace and forecasts market performance through 2029. The report examines dry eye syndrome’s etiology, diagnosis, and treatment and provides in-depth coverage on the prevalence of dry eye, prescription therapeutics, over-the-counter lubricants, thermal expression, IPL, punctum plugs, and additional dry eye procedures and products.  

Product demand is forecast in units and dollars, and market shares are analyzed by product category. Twenty-five market competitors are profiled, with discussion of their products, strategic market position, background, and outlook. 

In 2024, Market Scope conducted an online survey of US ophthalmologists focused on diagnostic equipment to better understand industry dynamics, gain important insights into leading trends, and explore surgeons’ opinions on current and future technologies. Sponsors were given the opportunity to review survey questions and add additional questions. Email invitations were sent to US ophthalmologists and optometrists who had been individually confirmed and verified on market-scope.com to participate in the survey. Email invitations were sent on Nov. 1, 2024. There were 160 total complete, unique responses in the US.

Market Scope’s "2024 Retinal Disease Model" offers extensive country-level prevalence data and five-year forecasts for retinal diseases and conditions by age group for all countries with a population over a million.

This proprietary model takes into consideration the latest clinical research and demographic projections on a global scale and can be customized by geography and disease category to meet clients’ diverse needs. Disease models can be used to evaluate target markets for clinical-stage and commercial-stage products and gain insights into the volume and demographics of diseased populations.

The “2024 Premium Cataract Surgery Market Report” is designed to provide insights into the most important premium cataract surgery (PCS) markets in the world. We’ve selected and profiled 13 countries that collectively account for 84 percent of global PCS manufacturer revenue and provided a deep dive into each of these markets. Ranked by 2024 PCS manufacturer revenue, they are: the United States, China, Japan, France, Germany, Brazil, Canada, India, Spain, South Korea, Australia, the UK, and Italy.  

For each of these countries, the report focuses on specific characteristics considered vital to the understanding of the opportunities for companies planning to market premium cataract surgery devices or looking to assess the value of each market. 

The “2024 United States Cataract Atlas” provides a geographic analysis of the conventional and premium cataract surgery opportunity in 85 US metropolitan areas. Market Scope’s proprietary MedOp Index™ Analysis examines market potential and provides a benchmark against other metros. The atlas offers strategic insights into the top potential markets in the US, which companies often use throughout the development and commercialization processes to identify ideal clinical trial locations, develop launch strategies, define sales territories, allocate resources, and optimize sales and marketing initiatives.